DNA adduct formation and molecular analysis of in vivo lacI mutations in the mammary tissue of Big Blue rats treated with 7, 12-dimethylbenz[a]anthracene.
Recently we compared the lacI and Hprt mutant frequencies (MFs) and types of mutations in lymphocytes of Big Blue((R)) (BB) rats exposed to 7,12-dimethylbenz[a]anthracene (DMBA) under conditions that result in mammary gland tumors. In this study, we have examined the target mammary tissue for DMBA-induced DNA adducts, lacI MF and types of lacI mutations. Seven-week-old female BB rats were given single doses of 0, 20 or 130 mg/kg DMBA by gavage and the DNA adducts and lacI MFs in the mammary tissue were measured over a period of 14 days and 18 weeks, respectively, following treatment. The lacI MF in the mammary tissue increased for 10 weeks and then remained relatively constant; 130 mg/kg DMBA produced a 14-fold increase in the MF (255 +/- 50 x 10(-6) p.f.u.) over control MF (18. 3 +/- 4 x 10(-6) p.f.u.). (32)P-post-labeling analysis of DNA from mammary tissue and splenic lymphocytes of treated rats revealed two major adducts. Comparison of these adducts with DMBA standards indicated that the adducts formed by DMBA involved both G:C and A:T base pairs. DNA sequencing revealed that the majority of DMBA-induced lacI mutations were base pair substitutions and that A:T-->T:A (44% of the independent mutations) and G:C-->T:A (24% of the independent mutations) transversions were the predominant types. Furthermore, the mutational results revealed a 'hotspot' for a G-->T mutation in codon 95 (GTG-->TTG) of the lacI gene in mammary tissue. These results suggest that DMBA is highly mutagenic to lacI in mammary tissue and that adducts with both G:C and A:T base pairs participate in forming mutations in DMBA-treated BB rats.
Manjanatha
M G
MG
Department of Health and Human Services, Food and Drug Administration, National Center for Toxicological Research, Divisions of Genetic and Biochemical Toxicology, Jefferson, AR 72079, USA. mmanjanatha@nctr.fda.gov
Shelton
S D
SD
Culp
S J
SJ
Blankenship
L R
LR
Casciano
D A
DA
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000633:toxicity*; D019943:Amino Acid Substitution; D000818:Animals; D030801:Animals, Genetically Modified; D002273:Carcinogens / Q000633:toxicity*; D003062:Codon / Q000235:genetics; D018736:DNA Adducts; D004249:DNA Damage; D004252:DNA Mutational Analysis; D005260:Female; D016368:Frameshift Mutation; D007763:Lac Operon; D008214:Lymphocytes / Q000737:chemistry; D008321:Mammary Glands, Animal / Q000737:chemistry / Q000187:drug effects*; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics*; D009153:Mutagens / Q000633:toxicity*; D009154:Mutation; D009928:Organ Specificity; D017354:Point Mutation; D051381:Rats; D013154:Spleen / Q000166:cytology
D002273:Carcinogens; D003062:Codon; D018736:DNA Adducts; D009153:Mutagens; D015127:9,10-Dimethyl-1,2-benzanthracene